Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach

BACKGROUND: Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also...

Descripción completa

Detalles Bibliográficos
Autores principales: Caiola, Elisa, Falcetta, Francesca, Giordano, Silvia, Marabese, Mirko, Garassino, Marina C., Broggini, Massimo, Pastorelli, Roberta, Brunelli, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280460/
https://www.ncbi.nlm.nih.gov/pubmed/30514331
http://dx.doi.org/10.1186/s13046-018-0954-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280460/
https://www.ncbi.nlm.nih.gov/pubmed/30514331
http://dx.doi.org/10.1186/s13046-018-0954-5

Ejemplares similares